Biotech Losers: VIVUS, Inc. (NASDAQ:VVUS), Galena Biopharma (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals (NASDAQ:ACHN)

VIVUS, Inc. (NASDAQ:VVUS) announced that it will report financial results for the fourth quarter and year ended December 31, 2013 after the NASDAQ Market closes on Monday, February 24, 2014. VIVUS, Inc. (NASDAQ:VVUS) stock opened at $7.19 in last session, and closed at $6.80, while the day range of stock is $6.78 – $7.19. The stock showed a negative weekly performance of -1.16%.

Cantor Fitzgerald lowered shares of Galena Biopharma (NASDAQ:GALE) from a buy rating to a sell rating in a report released on Tuesday, TheFlyOnTheWall.com reports. Cantor Fitzgerald currently has $3.50 price objective on the stock. Galena Biopharma Inc (NASDAQ:GALE) stock opened at $3.72, in last session and closed at $3.60, by losing -5.01%. The 52 week range of the stock is $1.65 – $7.77. Company’s market capitalization is $378.85 million.

Geron Corporation (NASDAQ:GERN) announced the closing of its previously announced public offering of 22,500,000 shares of its common stock, as well as 3,375,000 additional shares of its common stock pursuant to the full exercise of the underwriters` option to purchase additional shares. Geron Corporation (NASDAQ:GERN) stock decreased -6.92% and finished the last session at $4.84. The EPS of the stock remained -0.35. Company’s market capitalization is $733.02 million.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 1:30 p.m. ET at The Boston Marriott Copley Place in Boston, MA. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock opened the session at $3.64, and closed the session at $3.47. The 52 week range of the stock remained $2.26 – $10.12 and the day range was $3.45 – $3.65.